Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 23Lymphoma, Large B-Cell, Diffuse 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Follicular 12Lymphoma 11Rhabdomyosarcoma 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Biphenotypic, Acute 7Recurrence 6Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 6Wilms Tumor 5Sarcoma, Ewing 5Neuroblastoma 5Neoplasms 5Lymphoma, Mantle-Cell 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Rhabdomyosarcoma, Embryonal 3Medulloblastoma 3Lymphoproliferative Disorders 3Lymphoma, T-Cell 3Down Syndrome 3Sarcoma 2Rhabdomyosarcoma, Alveolar 2Rhabdoid Tumor 2Plasmablastic Lymphoma 2Osteosarcoma 2

Interventions

Rituximab 2Radiotherapy, Intensity-Modulated 2pomalidomide 1dehydroftorafur 1Watchful Waiting 1Vincristine 1Taxes 1Prednisone 1Platinum 1Phantoms, Imaging 1Paclitaxel 1Nivolumab 1Matrix-M 1Magnetic Resonance Spectroscopy 1Gemcitabine 1Fluorouracil 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Cisplatin 1Blood Specimen Collection 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epstein-Barr Virus Infections × Vincristine × 90 days × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡